Enpr-EMA enables networking and collaboration with members from within and outside the European Union (EU), including academia and the pharmaceutical industry.
It acts as a platform for sharing good practices as well as a pan-European voice for promoting research into medicines for children.
The network does not perform clinical trials or fund studies or research or decide on areas for paediatric research, as this is the responsibility of Member States, the European Commission or each individual member organisation.
For more information, see:
Enpr-EMA maintains a database of its member research networks and centres. The database is fully searchable and provides easy access to data about each Enpr-EMA network:
Enpr-EMA's main objective is to facilitate studies in order to increase the availability of authorised medicines for children. It works by:
For more information, see Enpr-EMA activities.
EMA is responsible for:
Enpr-EMA members perform research in children, from newborns to adolescents, in multiple therapeutic areas, and ranging from pharmacokinetics to pharmacovigilance.
Networks, centres, or investigators, specialised in paediatrics, and other parties interested in becoming members of Enpr-EMA should complete the self-assessment form on Enpr-EMA Network Database: Contact
To be accepted as a member, a network must demonstrate that it fulfills defined recognition criteria, such as:
For more information on the recognition criteria, see:
Membership categorisation was revised in 2021 and is organised in three categories:
Category 1 networks are part of the operational centre of Enpr-EMA, sharing responsibility for the network's long- and short-term strategy. For more information, see:
Enpr-EMA holds annual workshops at EMA's premises to discuss requirements, barriers and opportunities for high-quality clinical studies in children. They are open to all stakeholders.
These workshops enable Enpr-EMA to set priority tasks for the following year, based on feedback from stakeholders.
Further information and meeting materials are available on the meeting pages:
Enpr-EMA also organises subject-specific ad-hoc workshops, in line with its priority tasks:
Enpr-EMA regularly publishes newsletters to provide updates on its activities to its members and stakeholders:
For more information, see Enpr-EMA activities.
For more information, see Enpr-EMA activities.
Enpr-EMA members can offer pharmaceutical companies advice and expert information during all stages of paediatric medicine development.
Enpr-EMA recommends, in particular, that medicine developers involve paediatric research networks when developing a paediatric investigation plan.
Enp-EMA has published guidance for pharmaceutical companies on how to engage with paediatric research networks, including information on the services they offer:
Enpr-EMA and EMA's micro, small and medium-sized enterprises (SMEs) office offer support in setting up partnerships between SMEs and academic investigators in paediatric medicine research, as these groups often experience difficulty finding partners that complement their research interests.
To help develop networking opportunities and partnerships, the Enpr-EMA secretariat can provide information on:
Enpr-EMA invites networks, investigators and clinical-trial centres looking for pharmaceutical industry partners in the paediatric-medicine field to send the following information about their projects to enprema@ema.europa.eu: